BNP Paribas Financial Markets
FLNA

BNP Paribas Financial Markets’s Filana Therapeutics FLNA Stock Holding History

BNP Paribas Financial Markets’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$718 Sell
425
-10,584
-96% -$21.8K ﹤0.01% 5505
2025
Q4 		$21.8K Sell
11,009
-6,201
-36% -$19.9K ﹤0.01% 5000
2025
Q3 		$50.1K Sell
17,210
-73,691
-81% -$169K ﹤0.01% 4601
2025
Q2 		$165K Buy
90,901
+660
+0.7% +$1.17K ﹤0.01% 3846
2025
Q1 		$135K Buy
90,241
+25,680
+40% +$64.8K ﹤0.01% 3916
2024
Q4 		$152K Buy
64,561
+55,813
+638% +$980K ﹤0.01% 4007
2024
Q3 		$257K Buy
8,748
+5,250
+150% +$121K ﹤0.01% 3161
2024
Q2 		$43.2K Sell
3,498
-17,387
-83% -$367K ﹤0.01% 3482
2024
Q1 		$424K Buy
20,885
+1,786
+9% +$41.2K ﹤0.01% 2929
2023
Q4 		$430K Sell
19,099
-1,319
-6% -$27.9K ﹤0.01% 2876
2023
Q3 		$340K Buy
20,418
+9,973
+95% +$198K ﹤0.01% 2905
2023
Q2 		$256K Sell
10,445
-5,599
-35% -$135K ﹤0.01% 2922
2023
Q1 		$387K Buy
16,044
+10,383
+183% +$288K ﹤0.01% 2873
2022
Q4 		$167K Sell
5,661
-123,531
-96% -$4.44M ﹤0.01% 3067
2022
Q3 		$5.4M Sell
129,192
-92,073
-42% -$2.49M 0.01% 1334
2022
Q2 		$6.22M Buy
221,265
+217,805
+6,295% +$5.5M 0.01% 1135
2022
Q1 		$129K Sell
3,460
-17,094
-83% -$724K ﹤0.01% 3284
2021
Q4 		$898K Buy
20,554
+13,682
+199% +$717K ﹤0.01% 2662
2021
Q3 		$427K Buy
6,872
+5,405
+368% +$451K ﹤0.01% 2807
2021
Q2 		$125K Sell
1,467
-8,484
-85% -$454K ﹤0.01% 2979
2021
Q1 		$447K Buy
9,951
+3,776
+61% +$149K ﹤0.01% 2630
2020
Q4 		$42.1K Sell
6,175
-125
-2% -$1.12K ﹤0.01% 3632
2020
Q3 		$72.5K Buy
6,300
+5,432
+626% +$24.5K ﹤0.01% 3283
2020
Q2 		$2.67K Buy
+868
New +$3.94K ﹤0.01% 4153
2015
Q2 		– Sell
-132
Closed -$1.74K – 3609
2015
Q1 		$1.74K Buy
+132
New +$1.78K ﹤0.01% 3491
2014
Q4 		– Sell
-328
Closed -$8.98K – 2965
2014
Q3 		$8.98K Buy
328
+244
+290% +$7.41K ﹤0.01% 3643
2014
Q2 		$3.38K Hold
84
– – ﹤0.01% 2814
2014
Q1 		$3.35K Hold
84
– – ﹤0.01% 2520
2013
Q4 		$2.86K Buy
+84
New +$2.23K ﹤0.01% 3457

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BNP Paribas Financial Markets's FLNA Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Filana Therapeutics (FLNA) stake by 96% in Q1 2026, selling an estimated $21.8K and leaving 425 shares worth $718. The position accounts for ﹤0.01% of the portfolio, ranked #5505.

BNP Paribas Financial Markets first reported a position in FLNA in Q4 2013 and has held it in 29 quarters since. The position peaked at $6.22M in Q2 2022. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • BNP Paribas Financial Markets held 425 shares of Filana Therapeutics worth $718 as of Q1 2026.
  • BNP Paribas Financial Markets sold 10,584 Filana Therapeutics shares in Q1 2026, an estimated $21.8K.
  • Filana Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5505 holding.
  • BNP Paribas Financial Markets first reported a position in Filana Therapeutics in Q4 2013 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Filana Therapeutics position peaked at $6.22M in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.